FDA rejects NASH drug
Sign Up to like & getrecommendations! Published in 2020 at "Nature Reviews Drug Discovery"
DOI: 10.1038/d41573-020-00126-9
Abstract: cholic acid for fibrosis due to nonalcoholic steatohepatitis (NASH), another setback for an indication beset with failures. NASH is a form of liver disease that is marked by excessive fat accumulation, inflammation and cellular damage… read more here.
Keywords: nash drug; liver; drug; obeticholic acid ... See more keywords